Open Access


Read more
image01

Online Manuscript Submission


Read more
image01

Submitted Manuscript Trail


Read more
image01

Online Payment


Read more
image01

Online Subscription


Read more
image01

Email Alert



Read more
image01

Original Research Article | OPEN ACCESS

Inhibitory effect of platinum (II) complex of curcumin on non-small cell lung cancer via the PI3K-AKT pathway

Yu Wang, Chen Li

Molecular Testing Center, The First Affiliated Hospital of Jinzhou Medical University, JinZhou 121000, Liao Ning Province, China;

For correspondence:-  Chen Li   Email: re1162@163.com   Tel:+8613841629131

Accepted: 28 August 2018        Published: 30 September 2018

Citation: Wang Y, Li C. Inhibitory effect of platinum (II) complex of curcumin on non-small cell lung cancer via the PI3K-AKT pathway. Trop J Pharm Res 2018; 17(9):1771-1776 doi: 10.4314/tjpr.v17i9.13

© 2018 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To study the effect of platinum (II) complex of curcumin (PCC) on non-small cell lung cancer (NSCLC) using human NSCLC cell line A549. 
Methods: The anti-proliferative and apoptotic effects of PCC against NSCLC were investigated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), Annexin V-FITC/propidium iodide double staining, quantitative real-time polymerase chain reaction (qRT-PCR), and western blot assays.
Results: First, MTT assay and Annexin V-FITC/propidium iodide double staining results revealed that PCC possesses strong anti-cancer potency and high safety, when compared with cisplatin. Western blotting and qRT-PCR results showed that PCC inhibited the viability of NSCLC cells, decreased the expressions of PI3K, VEGF, AKT and Bcl-2, and upregulated the expression of PTEN.
Conclusion: These results indicate that PCC promotes apoptosis in A549 cells via PTEN/PI3K/AKT signaling pathways.

Keywords: Platinum-curcumin complex, Non-small cell lung cancer, Apoptosis, PI3K-AKT

Impact Factor
Thompson Reuters (ISI): 0.6 (2023)
H-5 index (Google Scholar): 49 (2023)

Article Tools

Share this article with



Article status: Free
Fulltext in PDF
Similar articles in Google
Similar article in this Journal:

Archives

2024; 23: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10. 
2023; 22: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2022; 21: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2021; 20: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2020; 19: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2019; 18: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2018; 17: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2017; 16: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2016; 15: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2015; 14: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2014; 13: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2013; 12: 
1,   2,   3,   4,   5,   6. 
2012; 11: 
1,   2,   3,   4,   5,   6. 
2011; 10: 
1,   2,   3,   4,   5,   6. 
2010; 9: 
1,   2,   3,   4,   5,   6. 
2009; 8: 
1,   2,   3,   4,   5,   6. 
2008; 7: 
1,   2,   3,   4. 
2007; 6: 
1,   2,   3,   4. 
2006; 5: 
1,   2. 
2005; 4: 
1,   2. 
2004; 3: 
1. 
2003; 2: 
1,   2. 
2002; 1: 
1,   2. 

News Updates